TCT 2021 | Advances in GvHD and maintenance following transplant

Name: Advances in GvHD and maintenance following transplant
Uploaded: 2021-02-05T00:00:00Z
Duration: 49 s
Description: Katie Maurer, MD, PhD, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, explores exciting updates in therapies for steroid-refractory graft-versus-host disease (GvHD), as well as the use of maintenance therapies following transplantation. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Katie Maurer • 5 Feb 2021

TCT 2021

General

Katie Maurer, MD, PhD, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA, explores exciting updates in therapies for steroid-refractory graft-versus-host disease (GvHD), as well as the use of maintenance therapies following transplantation. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.